Prime Therapeutics supports FDA's updated biosimilar recommendations

New approach aligns with long-standing biosimilar strategy EAGAN, Minn., Oct. 30, 2025 /PRNewswire/ -- Prime Therapeutics LLC (Prime) released the following statement on the U.S. Food and Drug Administration's (FDA) recent biosimilar announcement: "Prime strongly supports the...